Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody

Journal of Infectious Diseases

Volumn 210, Issue 2, 2014, Pages 200-208

  Van Dolleweerd, Craig J ^a   Teh, Audrey Y H ^a   Banyard, Ashley C ^d   Both, Leonard ^a   Lotter Stark, Hester C T ^b   Tsekoa, Tsepo ^b   Phahladira, Baby ^c   Shumba, Wonderful ^c   Chakauya, Ereck ^b   Sabeta, Claude T ^c   Gruber, Clemens ^e   Fooks, Anthony R ^d   Chikwamba, Rachel K ^b   Ma, Julian K C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^c ONDERSTEPOORT VETERINARY INSTITUTE   (South Africa)

^d VETERINARY LABORATORIES AGENCY   (United Kingdom)

^e UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

Nicotiana tabacum

Indexed keywords

GLYCOPEPTIDE; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY E559; NEUTRALIZING ANTIBODY; RABIES IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

AGROBACTERIUM TUMEFACIENS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CODON; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; HYBRIDOMA; MOLECULAR CLONING; MOLECULAR WEIGHT; NONHUMAN; PLANT GENE; PLANT LEAF; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEOMICS; RABIES; RABIES VIRUS; SURVIVAL RATE; TOBACCO; TRANSGENIC PLANT; VIRUS NEUTRALIZATION; VIRUS STRAIN;

MONOCLONAL ANTIBODY; NICOTIANA TABACUM; POST-EXPOSURE PROPHYLAXIS; RABIES; RIG;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CRICETINAE; DISEASE MODELS, ANIMAL; HUMANS; MESOCRICETUS; MICE; PLANTS, GENETICALLY MODIFIED; RABIES; RABIES VIRUS; RECOMBINANT PROTEINS; TOBACCO;

EID: 84903940385     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu085     Document Type: Article

References (46)

1. World Health Organization. WHO Fact Sheet no. 99. Available at: http:// web.archive.org/web/20130310122553/http://www.who.int/mediacentre/ factsheets/fs099/en/index.html. Accessed 19 February 2014.
2. Hampson K, Dobson A, KaareM, et al. Rabies exposures, post-exposure prophylaxis and deaths in a region of endemic canine rabies. PLoS Negl Trop Dis 2008; 2:e339.
3. Dodet B. The fight against rabies in Africa: from recognition to action. Vaccine 2009; 27:5027-32.
4. Fooks AR. Rabies remains a 'neglected disease'. Euro Surveill 2005; 10:211-2.
5. Both L, Banyard AC, van Dolleweerd C, Horton DL, Ma JK, Fooks AR. Passive immunity in the prevention of rabies. Lancet Infect Dis 2012; 12:397-407.
6. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis 2002; 2:327-43. (Pubitemid 34595973)
7. Hemachudha T, Laothamatas J, Rupprecht CE. Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol 2002; 1:101-9. (Pubitemid 37163495)
8. Ertl HC. Novel vaccines to human rabies. PLoS Negl Trop Dis 2009; 3: e515.
9. Rupprecht CE, Gibbons RV. Clinical practice: prophylaxis against rabies. N Engl J Med 2004; 351:2626-35. (Pubitemid 39628584)
10. Warrell M. Rabies and African bat lyssavirus encephalitis and its prevention. Int J Antimicrob Agents 2010; 36(Suppl 1):S47-52.
11. Satpathy DM, Sahu T, Behera TR. Equine rabies immunoglobulin: a study on its clinical safety. J Indian Med Assoc 2005; 103:238, 41-2.
12. World Health Organization.WHOconsultation on a rabies monoclonal antibody cocktail for rabies post exposure treatment. Geneva: WHO, 23-24 May 2002. World Health Organization, Geneva, Switzerland, 2002. Available at: http://web.archive.org/web/20100525173651/http:// www.who.int/rabies/vaccines/ en/mabs-final-report.pdf. Accessed 19 February 2014.
13. World Health Organization. WHO expert consultation on rabies (1st report). WHO technical report series 931. Geneva, Switzerland, 2005.
14. Bakker AB, Marissen WE, Kramer RA, et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 2005; 79:9062-8. (Pubitemid 40934817)
15. Müller T, Dietzschold B, Ertl H, et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 2009; 3:e542.
16. Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JK, Fooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine 2013; 31:1553-9.
17. Goudsmit J, Marissen WE, Weldon WC, et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 2006; 193: 796-801.
18. Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 2003; 188:53-6. (Pubitemid 36829741)
19. Dietzschold B, Gore M, Casali P, et al. Biological characterization of human monoclonal antibodies to rabies virus. J Virol 1990; 64:3087-90. (Pubitemid 20171306)
20. Enssle K, Kurrle R, Kohler R, et al. A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 1991; 10:547-56.
21. Champion JM, Kean RB, Rupprecht CE, et al. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 2000; 235:81-90. (Pubitemid 30089786)
22. Hanlon CA, DeMattos CA, DeMattos CC, et al. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in postexposure prophylaxis. Vaccine 2001; 19:3834-42. (Pubitemid 32566304)
23. Muhamuda K, Madhusudana SN, Ravi V. Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies. Hum Vaccin 2007; 3:192-5. (Pubitemid 47598178)
24. Paul M, van Dolleweerd C, Drake PM, et al. Molecular pharming: future targets and aspirations. Hum Vaccin 2011; 7:375-82.
25. Ko KS, Tekoah Y, Rudd PM, et al. Function and glycosylation of plantderived antiviral monoclonal antibody. P Natl Acad Sci USA 2003; 100:8013-8. (Pubitemid 36760086)
26. Schumacher CL, Dietzschold B, Ertl HC, Niu HS, Rupprecht CE, Koprowski H. Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J Clin Invest 1989; 84:971-5. (Pubitemid 19228371)
27. de Kruif J, Bakker AB, Marissen WE, et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Ann Rev Med 2007; 58:359-68. (Pubitemid 46706520)
28. Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008; 26:5922-7.
29. Sloan SE, Hanlon C, Weldon W, et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 2007; 25:2800-10. (Pubitemid 46412574)
30. Gogtay N, Thatte U, Kshirsagar N, et al. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, doseescalation phase 1 study in adults. Vaccine 2012; 30:7315-20.
31. Both L, van Dolleweerd C, Wright E, et al. Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans. FASEB J 2013; 27:2055-65.
32. Schneider LG, Meyer S. Antigenic determinants of rabies virus as demonstrated by monoclonal antibody. In: Bishop DH, Compans RW, eds. The Replication of Negative Strand Viruses: Developments in Cell Biology. Vol. 7. North Holland: Elsevier, 1981:947-83.
33. Kissling RE. Growth of rabies virus in non-nervous tissue culture. Proc Soc Exp Biol Med 1958; 98:223-5.
34. Hehle VK, Paul MJ, Drake PM, Ma JK, van Dolleweerd CJ. Antibody degradation in tobacco plants: a predominantly apoplastic process. BMC biotechnology 2011; 11:128.
35. Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 2008; 8:2858-71.
36. Cliquet F, Aubert M, Sagne L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 1998; 212: 79-87. (Pubitemid 28288189)
37. Brookes SM, Parsons G, Johnson N, McElhinney LM, Fooks AR. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 2005; 23:4101-9. (Pubitemid 40814585)
38. Dean DJ, Abelseth MK, Atanasiu P. The fluorescent antibody test. In: Meslin F-X, Kaplan MM, Koprowski H, eds. Laboratory Techniques in Rabies. 4th ed. Geneva: WHO, 1996:88-95.
39. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. 5th Edition ed. Bethesda, Maryland: National Institutes of Health, 1991.
40. Badrane H, Bahloul C, Perrin P, Tordo N. Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 2001; 75:3268-76. (Pubitemid 32225890)
41. McCormick AA, Reddy S, Reinl SJ, et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A 2008; 105:10131-6.
42. Whaley KJ, Hiatt A, Zeitlin L. Emerging antibody products and Nicotiana manufacturing. Hum Vaccines 2011; 7:349-56.
43. Horton DL, McElhinney LM, Marston DA, et al. Quantifying antigenic relationships among the lyssaviruses. J Virol 2010; 84:11841-8.
44. Cabanes-Macheteau M, Fitchette-Laine AC, Loutelier-Bourhis C, et al. N-glycosylation of a mouse IgG expressed in transgenic tobacco plants. Glycobiology 1999; 9:365-72. (Pubitemid 29182152)
45. Triguero A, Cabrera G, Rodriguez M, et al. Differential N-glycosylation of a monoclonal antibody expressed in tobacco leaves with and without endoplasmic reticulum retention signal apparently induces similar in vivo stability in mice. Plant Biotechnol J 2011; 9:1120-30.
46. Lee JH, Park DY, Lee KJ, et al. Intracellular reprogramming of expression, glycosylation, and function of a plant-derived antiviral therapeutic monoclonal antibody. PloS one 2013; 8:e68772.